The initiatives are being funded with C$24 million over two years and will focus on acute leukemia, immuno-oncology, and brain, ovarian, and pancreatic cancer.
Researchers demonstrated the feasibility of finding multiple myeloma mutations with a new circulating tumor DNA sequencing method known as LB-Seq.
In two studies, researchers sequenced nearly 500 tumors to uncover hallmarks of aggressive prostate cancer.
A team led by University of Toronto researchers developed the signature as a clinical assay that could predict treatment response.
Based on the results, the researchers, based in Toronto, have initiated a clinical study in Ontario, called OCTANE, that involves a number of cancer centers in the province.
Results from a recent study clarify some conflicting prior determinations, and provide a new rationale to further explore the FCGR2A biomarker in prospective trials.
The initial phase of GENIE, which stands for Genomics, Evidence, Neoplasia, Information, Exchange, involves seven founding members and two informatics partners.
Canada's Hospital for Sick Children and the University Health Network's Princess Margaret Cancer Centre are piloting a new IT infrastructure for analyzing genetic and other kinds of biomedical data.
This story has been updated to include additional information from a US survey on people's attitudes about cost of genetic testing. Originally published June 4.
By a GenomeWeb staff reporter
A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.
The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.
In Nature this week: investigation into the genetics of medulloblastoma, and more.
A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.